GlassScriptPhysician profile
Travis G Hailstone
NPI 1215165238
$8,304.84
in general payments reported to CMS, 2019-2025
51 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $852 · 2021: $2,117 · 2022: $907 · 2023: $926 · 2024: $1,203 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,314 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.96 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,402.46 | 2019-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,258.93 | 2021 | |
| Amgen INC. | $570.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $543.18 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Antares Pharma, INC. | $542.81 | 2019-2025 | Xyosted |
| Abbvie INC. | $464.60 | 2019-2025 | |
| Pfizer INC. | $403.24 | 2019-2025 | |
| Novo Nordisk INC | $363.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.79 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $283.93 | 2019-2024 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $231.71 | 2019-2025 | |
| Allergan, INC. | $183.40 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $166.36 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $133.83 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.91 | 2023-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Hailstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.